Walgreens Boots Alliance Inc (NASDAQ:WBA) is expanding its specialty pharmacy services to include gene and cell therapy solutions, aiming to enhance patient outcomes and value for stakeholders. The expansion includes the introduction of Walgreens Specialty Pharmacy, which will operate four central specialty pharmacies and nearly 300 community-based specialty pharmacies. The initiative is supported by over 1,500 specialty-trained pharmacists and 5,000 patient advocacy support members. Walgreens stock has lost over 48% in the last 12 months but is trading higher by 0.79% in premarket. Investors can also gain exposure to Walgreens stock through Invesco High Yield Equity Dividend Achievers ETF (NASDAQ:PEY) and Invesco Dow Jones Industrial Average Dividend ETF (NYSE:DJD).